Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Physician's Global Assessment (PGA) response, ie, the proportion of subjects achieving a PGA of "clear" or "almost clear"

Outcome Time Frame:

Week 16

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A3921078

NCT ID:

NCT01276639

Start Date:

March 2011

Completion Date:

April 2013

Related Keywords:

• Psoriasis
• chronic
• severe
• moderate
• treatment
• safety
• efficacy
• CP-690
• 550
• Plaque Psoriasis
• Psoriasis Vulgaris
• Psoriasis